Personalizing Lung Cancer Care Through Biomarkers and Precision Medicine With Blanca Ledezma, MSN, NP
Keira Smith
Expert Analysis
In this interview with Oncology Data Advisor, Blanca Ledezma, MSN, NP, elucidates the current landscape of therapeutically actionable biomarkers in lung cancer and the promising future of precision medicine in this field. In addition, she explains the clinical applications for lung cancer biomarkers in nursing practice, including unique toxicity management and patient education for novel therapies.  
Blood Cancer Awareness Month: Exploring Patient-Reported Outcomes With Rahul Banerjee, MD, FACP, and Ajay Major, MD, MBA
Keira Smith
Expert Analysis
Recently, Dr. Rahul Banerjee, Assistant Professor at the University of Washington and Editorial Board member for Oncology Data Advisor, spoke with Dr. Ajay Major, Assistant Professor at the University of Colorado, in a live interview discussion in honor of Blood Cancer Awareness Month. Dr. Banerjee and Dr. Major engaged in a riveting conversation about the role of patient-reported outcomes (PROs) in lymphoma and myeloma, including how to interpret them and how to include them when designing research.  
Addressing Clinical Trial Accrual of Minority Patients With Donna Catamero, NP
Lyn Brook
Expert Analysis
At the recent International Myeloma Society (IMS) Annual Meeting, Donna Catamero, NP, the Associate Director of Myeloma Translational Research at Mount Sinai Hospital, presented her abstract regarding increasing clinical trial accrual of minority patients. In this interview, Ms. Catamero discusses her presentation, the disproportionate burden that minority patients experience, and why she believes the health care team should take action to create an equal space for everyone in the clinic.  
Caring for Patients Receiving CAR T-Cell Therapy With Joshua Sasine, MD, PhD
Keira Smith
Expert Analysis
In this interview with Oncology Data Advisor, Dr. Joshua Sasine, Hematologist-Oncologist at Cedars-Sinai Medical Center, discusses the factors that make patients suitable candidates for chimeric antigen receptor (CAR) T-cell therapy, strategies to minimize the unique toxicities associated with these treatments, and the future of the use of CAR T-cell therapy in the outpatient setting.  
Determining Patient Selection for CAR T-Cell Therapy in Multiple Myeloma With Beth Faiman, PhD, CNP
Keira Smith
Expert Analysis
While chimeric antigen receptor (CAR) T–cell therapy has revolutionized the treatment landscape for multiple myeloma, the high demand for these efficacious therapies has made patient selection a challenge. At the recent International Myeloma Society Annual Meeting, Beth Faiman, a Nurse Practitioner at the Cleveland Clinic, presented a poster about a clinical factor scoring system that she and her colleagues have developed to aid in these decisions. In this follow-up interview with Oncology Data Advisor, Dr. Faiman explains how this innovative system works and the next steps to validate it and implement it into practice in the future.  
No One Left Alone: Taking the First Steps to Address Cancer Disparities With Kashyap Patel, MD
Keira Smith
Expert Analysis
At the recent International Myeloma Society (IMS) Annual Meeting, Dr. Kashyap Patel, CEO of Carolina Blood and Cancer Care Associates and President of the Community Oncology Alliance, spoke about practical solutions for addressing disparities in multiple myeloma in the United States. In this follow-up interview with Oncology Data Advisor, Dr. Patel digs deep into the multifaceted factors that contribute to cancer disparities and shares his pioneering work that aims to ensure that every patient with cancer receives equitable access to care.  
Guiding Breast Cancer Surgical Decisions With Valerie Brutus, MD, FACS
Keira Smith
Expert Analysis
In this interview with Oncology Data Advisor, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center, discusses the significance of Magtrace™, a liquid tracer which has recently become a game changer in guiding surgical decisions for patients with breast cancer.  
The Future of MRD in Multiple Myeloma Treatment Decision Making With Rahul Banerjee, MD, and Ben Derman, MD
Keira Smith
Expert Analysis
In this interview, Oncology Data Advisor Editorial Board member Dr. Rahul Banerjee speaks with Dr. Ben Derman, Assistant Professor of Medicine at the University of Chicago, about his research regarding measurable residual disease (MRD) detection in multiple myeloma and its potential role in guiding treatment decisions.  
Understanding the Research on Novel Treatments and Nutritional Interventions for Multiple Myeloma With Urvi Shah, MD
Keira Smith
Expert Analysis
During the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Urvi Shah from Memorial Sloan Kettering Cancer Center sat down with Oncology Data Advisor to share her perspectives on the exciting research that was presented in the poster discussion session she chaired on novel therapies for multiple myeloma. In addition, Dr. Shah explains more about her work to impact patients' quality of life and outcomes through nutritional interventions.This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. 
Please Move: Get Your Oncology Patients Exercising With Karen Basen-Engquist, PhD, MPH
Lyn Brook
Expert Analysis
At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Karen Basen-Engquist, PhD, MPH, Director of the Center for Energy Balance in Cancer Prevention and Survivorship at The University of Texas MD Anderson Cancer Center, sat down with Oncology Data Advisor after presenting her education session on behavioral strategies to get your patients with cancer exercising and why it is important.  
World Lung Cancer Day With Beth Sandy, MSN, CRNP, and Corey Langer, MD
Keira Smith
Expert Analysis
On August 1st, Oncology Data Advisor hosted a live panel discussion in honor of World Lung Cancer Day, featuring Beth Sandy, MSN, CRNP, and Corey Langer, MD, both of the University of Pennsylvania Abramson Cancer Center. Ms. Sandy and Dr. Langer discussed the improvements in survival that have occurred in recent years due to the development of novel therapies, groundbreaking developments in the fields of immunotherapy and targeted therapy, and exciting advances that lay on the horizon for patients with lung cancer in the coming years.  
Understanding the Current Landscape of Chemotherapy-Induced Neutropenia With Maura Abbott, NP, MSN, PhD
Lyn Brook
Expert Analysis
Chemotherapy-induced neutropenia (CIN) is a common and potentially life-threatening consequence of chemotherapy, as it may lead to serious infections for patients with cancer. These infections result in hospital stays, increased morbidity and mortality, and considerable financial burden. In this interview, Dr. Maura Abbott explains the importance of managing and educating patients about CIN.  
Guiding Colorectal Cancer Treatment Decisions by Using ctDNA With Jeanne Tie, MD, MBChB, FRACP
Elizabeth Heller, PhD
Expert Analysis
At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Jeanne Tie spoke with Oncology Data Advisor to share more about her presentation regarding the clinical utility of circulating tumor DNA (ctDNA) analysis to guide treatment decision making for patients with colorectal cancer.  
Advancing Treatment for Non–Small Cell Lung Cancer: Exploring the Results of Adagrasib With Alexander Spira, MD, PhD, FACP
Lyn Brook
Expert Analysis
At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Alexander Spira, MD, PhD, FACP, Director of the Thoracic and Phase I Program at the Virginia Cancer Specialists, the US Oncology Network, met with Oncology Data Advisor to discuss his presentation about adagrasib for KRAS G12–mutated non–small cell lung cancer with active central nervous system (CNS) metastases.  
Increasing Medical Student Confidence When Treating LGBTQIA+ Patients With Cherry Au, MD
Lyn Brook
Expert Analysis
Following the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Cherry Au, MD, of Rush University Medical Center, spoke with Oncology Data Advisor to discuss her abstract, Medical Student Clinical Cultural Awareness in Cancer Care of Sexual and Gender Minorities.  
Creating an Inclusive Environment in Your Oncology Practice With Mark Fleming, MD
Lyn Brook
Expert Analysis
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, Dr. Mark T. Fleming and colleagues, from the Virginia Oncology Associates, presented their poster about their initiative to foster a culture of inclusion in an independent community oncology and hematology practice that specializes in the diagnosis and treatment of cancer and blood disorders.  
Understanding Bias Experienced by Caregivers Regarding Cancer-Related Decisions With Nick Dionne-Odom, PhD, RN
Lyn Brook
Expert Analysis
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Nick Dionne-Odom, PhD, RN, Assistant Professor in the University of Alabama at Birmingham School of Nursing and School of Geriatric and Palliative Care, presented a poster about his clinical trial exploring cancer-related decisions and the health care team bias experienced by caregivers regarding these decisions. Afterwards, he spoke with Oncology Data Advisor to shed further light on the trial's results.  
The Future of Cancer Care is Digital: Debra Patt, MD, PhD, MBA, FASCO
Lyn Brook
Expert Analysis
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Debra Patt, MD, PhD, MBA, FASCO, Executive Vice President of Texas Oncology and Clinical Professor at Dell Medical School at the University of Texas at Austin, presented her research regarding digital health solutions. Afterwards, she spoke with Oncology Data Advisor to further elucidate on the implications of digital health care for oncology practice. 
Fundamental Considerations in Radiation Oncology With Charles Simone, MD, FACRO
Elizabeth Heller, PhD
Expert Analysis
At the recent Oncology Nursing Society (ONS) Congress in Anaheim, California, Charles B. Simone, II, MD, FACRO, explained the concepts underlying the treatment of cancer with radiation therapy. In this interview with Oncology Data Advisor, Dr. Simone discusses the different types of radiation treatments and some considerations in choosing treatment. He also shares current evidence from his research about synergy between radiation therapy and checkpoint inhibitors or chemotherapy. 
Discussing Patient-Reported Hope in Early Phase Clinical Trials With Debra Lundquist, PhD, RN
Lyn Brook
Expert Analysis
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, Debra Lundquist, PhD, RN, of Massachusetts General Hospital and colleagues presented their poster that sought to bridge the gap between recent advances in individual therapy which led to improved outcomes and a better understanding of patient-reported hope, quality of life, symptom burden, and coping mechanisms in early phase clinical trial participants.  

Copyright © 2022 Oncology Data Advisor. All rights reserved.